Anti-VEGF treatment is a relatively recent development and is considered superior and more effective than older options, such as photodynamic therapy, in the treatment of wet AMD and macular edema. Lucentis is one of four anti-VEGF drugs on the market, alongside EYLEA (aflibercept), Beovu (brolucizumab), and Avastin (bevacizumab). Like Lucentis, EYLEA and Beovu are approved by the FDA for treating wet AMD and other eye conditions, while Avastin is approved to treat several cancers. While Avastin is not approved to treat wet AMD or other eye conditions, it is considered safe and effective and is often used because it is cheaper. However, this may depend on where you live and your insurance coverage. While other types of treatment, including high-dose intravitreal triamcinolone acetonide (ITVA) and atypical protein kinase C (aPKC) inhibitors, have been touted as possible alternatives, anti-VEGF treatment is usually still considered the first-line treatment for wet AMD. Alternative treatment may be used for macular edema, including steroids, eye drops, and laser treatment, but these are often when the underlying cause is different from those discussed in this article. You should speak to your doctor about your specific condition and the treatment options available.